ESMO 2017 Highlights in Upper GI Cancers: Clinically Relevant Combo Studies

Speaker: Stefano Cascinu

Stefano Cascinu reports that practice changing results were presented for both resectable and advanced upper GI cancers during the ESMO 2017 Congress.

Stefano Cascinu reports that practice changing results were presented for both resectable and advanced upper GI cancers during the ESMO 2017 Congress.

Salah-Eddin Al-Batran explains that the FLOT4 study aimed at improving the overall survival of patients with resectable oesophago-gastric cancer. It showed that FLOT4 regimen improved resectional rate, and both RFS and OS at 5 years, and confirms the benefit of preoperative chemotherapy in this setting.

Josep Tabernero presents the results of the JACOB study and explains that it was designed to understand whether the addition of pertuzumab to conventional treatment in HER2+ metastatic oesophago-gastric cancer patients would translate into better OS as it does for breast cancer patients. The final analysis didn’t result in a statistically significant benefit in OS, although there was a clear trend for some patients having better outcomes with the combination. So far, biological investigations to identify subgroups of patients responding better to the combination are ongoing.

Abstracts

  • LBA27_PR - Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)
  • 616O - Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB)

More resources from ESMO 2017 Congress